SEC Comment Letter 0000000000-23-009852 to Pyxis Oncology, Inc. (PYXS) (CIK 0001782223) (PYXS)

Pyxis Oncology, Inc. (PYXS) (CIK 0001782223)
Date: Sept. 6, 2023 · CIK: 0001782223 · Accession: 0000000000-23-009852

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 001-40881

Date

September 6, 2023

Author

Not clearly detected

Form

UPLOAD

Company

Pyxis Oncology, Inc. (PYXS) (CIK 0001782223)

Letter

United States securities and exchange commission logo September 6, 2023 Pamela Connealy Chief Financial Officer Pyxis Oncology, Inc. 321 Harrison Avenue Boston, MA 02118 Re:Pyxis Oncology, Inc. Form 10-K for the fiscal year ended December 31, 2022 Form 10-Q for the quarterly period ended June 30, 2023 File No. 001-40881 Dear Pamela Connealy: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

United States securities and exchange commission logo
September 6, 2023
Pamela Connealy
Chief Financial Officer
Pyxis Oncology, Inc.
321 Harrison Avenue
Boston, MA 02118
Re:Pyxis Oncology, Inc.
Form 10-K for the fiscal year ended December 31, 2022
Form 10-Q for the quarterly period ended June 30, 2023
File No. 001-40881
Dear Pamela Connealy:
            We have completed our review of your filings.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io